Ключевые слова
Аннотация
Systemic sclerosis is a chronic autoimmune disease affecting multiple organs, including the lungs. Pulmonary fibrosis in systemic sclerosis significantly reduces lung function, leading to respiratory insufficiency and deterioration in quality of life. This article analyzes current approaches to managing pulmonary fibrosis in systemic sclerosis. The effectiveness of traditional immunosuppressive therapy, antifibrotic drugs, biological therapy, and targeted molecular treatments is reviewed. Individualized treatment strategies and results from recent clinical trials are also discussed. These modern approaches aim to stabilize lung function, slow disease progression, and improve patient quality of life.
Библиографические ссылки
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M., … & Flaherty, K. R. (2019). Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. The New England Journal of Medicine, 380(26), 2518–2528.
Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T., Anderson, M., … & Distler, O. (2016). Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. The Lancet, 387(10038), 2630–2640.
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., … & Group, S. S. S. (2006). Cyclophosphamide versus placebo in scleroderma lung disease. The New England Journal of Medicine, 354(25), 2655–2666.
Volkmann, E. R., Tashkin, D. P., Li, N., Kleerup, E. C., Kleerup, E., & Furst, D. E. (2017). Long-term follow-up of patients with systemic sclerosis receiving immunosuppressive therapy for interstitial lung disease. Arthritis & Rheumatology, 69(11), 2291–2301.
Allanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C., … & Lafyatis, R. (2015). Systemic sclerosis. Nature Reviews Disease Primers, 1, 15002.
Cottin, V., & Brown, K. K. (2019). Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research, 20, 13.
Hoffmann-Vold, A. M., Fretheim, H., Halse, A. K., Diederichsen, A. C., Garen, T., Andreassen, J., … & Midtvedt, Ø. (2019). Tracking impact of interstitial lung disease in systemic sclerosis in a longitudinal cohort. Annals of the Rheumatic Diseases, 78(5), 622–630.
Varga, J., & Abraham, D. (2007). Systemic sclerosis: a prototypic multisystem fibrotic disorder. Journal of Clinical Investigation, 117(3), 557–567.